These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38149948)

  • 1. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.
    Kapadia CD; Rosas G; Thakkar SG; Wu M; Torrano V; Wang T; Grilley BJ; Heslop HE; Ramos CA; Goodell MA; Lulla PD
    Cytotherapy; 2024 Mar; 26(3):261-265. PubMed ID: 38149948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.
    Goldsmith SR; Shouse G; Wong FL; Bosworth A; Iukuridze A; Chen S; Rhee JW; Mei M; Htut M; Janakiram M; Forman SJ; Pillai R; Budde LE; Armenian SH
    Transplant Cell Ther; 2024 Sep; 30(9):927.e1-927.e9. PubMed ID: 38871057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Frequency
    Seipel K; Frey M; Nilius H; Akhoundova D; Banz Y; Bacher U; Pabst T
    Curr Oncol; 2023 Dec; 30(12):10463-10476. PubMed ID: 38132396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
    Saini NY; Swoboda DM; Greenbaum U; Ma J; Patel RD; Devashish K; Das K; Tanner MR; Strati P; Nair R; Fayad L; Ahmed S; Lee HJ; Iyer SP; Steiner R; Jain N; Nastoupil L; Loghavi S; Tang G; Bassett RL; Jain P; Wang M; Westin JR; Green MR; Sallman DA; Padron E; Davila ML; Locke FL; Champlin RE; Garcia-Manero G; Shpall EJ; Kebriaei P; Flowers CR; Jain MD; Wang F; Futreal AP; Gillis N; Neelapu SS; Takahashi K
    Blood Cancer Discov; 2022 Sep; 3(5):385-393. PubMed ID: 35533245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
    Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
    Front Immunol; 2022; 13():858021. PubMed ID: 35432352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
    Eder LN; Martinovic D; Mazzeo P; Ganster C; Hasenkamp J; Thomson J; Trummer A; Haase D; Wulf G
    Curr Oncol; 2023 Jan; 30(1):1146-1150. PubMed ID: 36661736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.
    Panagiota V; Kerschbaum JF; Penack O; Stein CM; Arends CM; Koenecke C; Strzelecka PM; Kloos A; Wiegand L; Lasch A; Altwasser R; Halik A; Gabdoulline R; Thomson J; Weibl K; Franke GN; Berger C; Hasenkamp J; Ayuk F; Na IK; Beutel G; Keller U; Bullinger L; Wulf GG; Kröger N; Vucinic V; Heuser M; Damm F
    Hemasphere; 2023 Oct; 7(10):e957. PubMed ID: 37799345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crossroads of cancer therapies and clonal hematopoiesis.
    Singh A; Balasubramanian S
    Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
    Miller PG; Sperling AS; Brea EJ; Leick MB; Fell GG; Jan M; Gohil SH; Tai YT; Munshi NC; Wu CJ; Neuberg DS; Maus MV; Jacobson C; Gibson CJ; Ebert BL
    Blood Adv; 2021 Aug; 5(15):2982-2986. PubMed ID: 34342642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
    Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
    Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of clonal hematopoiesis for cellular therapies].
    Teipel R; von Bonin M; Stölzel F; Schetelig J; Thiede C; Bornhäuser M
    Inn Med (Heidelb); 2022 Nov; 63(11):1126-1132. PubMed ID: 36149441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations.
    Mangaonkar AA; Patnaik MM
    Am J Hematol; 2023 Jun; 98(6):951-964. PubMed ID: 36938794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T-cell therapies for lymphoma.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
    Cao G; Lei L; Zhu X
    Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CAR-T cells in lymphomas: Current and evolving role].
    Messéant O; Houot R
    Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Ye B; Sheng Y; Zhang M; Hu Y; Huang H
    Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
    Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
    Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
    Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.